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Introduction 
 
Within the last decade, much has been written on the impending impact of the Human Genome 
Project on human health.  A typical perspective was offered in 1995 as part of the submission of 
the Royal College of Physicians to the Science and Technology Committee of the U.K. House 
of Commons.  In describing the future contribution of genetics to medical practice it was stated 
that, ‘The process has scarcely begun and may not have a major clinical impact for many years; 
however it represents the change from empirical to rational management of disease and hence 
its significance can hardly be exaggerated’.  Clearly, any body of knowledge that could effect 
such a change would be of global importance, and if this and similar predictions prove to be 
correct, they would match in significance the revolution in medical practice provoked by the 
anatomical discoveries of the Renaissance period. 
 
The Human Genome Project was initiated in 1991, and by 2001, the first consensus sequence of 
the human genome was simultaneously published by publicly supported researchers 
(International Human Genome Sequencing Consortium 2001) and the privately financed Celera 
Genomics (Venter et al. 2001).  Access to the growing database on genome structure and 
function made available through the Human Genome Project has greatly assisted medical 
researchers, and as a result, by March 2003 over 14,000 single gene disorders affecting both the 
human nuclear and mitochondrial genomes had been identified (OMIM 2003). 
 
Of itself, the recognition of specific and often very rare mutations is unlikely to change medical 
practice or to impinge on the everyday lives of the vast majority of the world’s population.  
Data on the contribution of predisposing genes to common diseases is still rudimentary, and 
there is limited information on non-biological factors that influence the genetic structure of 
human populations and thereby govern the distribution and transmission of disease mutations.  
An appreciation of the importance of these topics has, however, gradually been emerging, 
accompanied by the establishment of two new academic disciplines, Community Genetics and 
Public Health Genetics.  The aim of this article is to briefly review the potential influence and 
effects of these changes on the future profile of genetic disease in industrialized and developing 
countries. 
 
The prevalence of genetic disease in industrialized and developing countries 
 
Preliminary evidence of a major change in the profile of human disease in industrialized 
countries was provided by a record-based study conducted in the U.K. at the Great Ormond 
Street Hospital for Children, London (Carter 1956).  Genetic disorders had been diagnosed in 
16.5% of childhood deaths in the hospital in 1914, but by 1954 this figure had risen to 37.5%.  
Over the same period, deaths described as ‘environmental’ had decreased from 68.0% of the 
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total to just 14.5%, reflecting the beneficial preventive effects of vaccination programmes for 
infectious diseases and the successful introduction of antibiotic therapy.  This epidemiological 
transition was affecting all industrialized countries, and by the 1970s, the growing social and 
financial burden of childhood genetic disease had already become a source of concern in the 
U.S.A. (Hall et al. 1978). 
 
Current estimates suggest that in the industrialized countries approximately 5% of individuals 
will exhibit symptoms of genetic disease by young adulthood.  However, if congenital 
anomalies are included the prevalence increases to some 8% of all live births (Baird et al. 1988).  
Comparable data are not separately available for developing countries, but in global terms it has 
been suggested that at least 7.6 million children per year are born with a severe congenital or 
genetic disorder (Alwan and Modell 2003). 
 
Because of the continuing importance of infectious disease and nutritional disorders in 
developing countries, it has been assumed that their burden of genetic disease is relatively 
unimportant.  While it is undoubtedly true that in proportional terms genetic disorders are 
responsible for a minority of childhood disease diagnosed in developing countries, in many 
parts of the world up to 40% of the population are carriers of an inherited haemoglobin disorder 
(Livingstone 1967).  Overall, this means that an estimated one in seven of the world’s 
population are carriers of a gene either for thalassaemia or a haemoglobin variant (WHO 2002).  
In both types of disorder, individuals who have inherited the causative mutations from each 
parent commonly have severe anaemia, and the vast majority of these people are resident in 
tropical regions. 
 
Demography, population genetics and genetic disease 
 
The social and demographic structures of populations play very significant roles in the 
distribution patterns of specific inherited disorders, albeit with marked differences between the 
industrialized and developing countries.  For example, following the onset of the Industrial 
Revolution in Europe, there was widespread population movement from the countryside into the 
rapidly expanding towns and cities.  These large-scale population changes resulted in the 
dissolution of historical local, regional and national boundaries, which in turn helped to exert a 
partial homogenizing effect on national gene pools.  Likewise, through time, large-scale 
migration from Europe to the Americas and Australasia resulted in significant mixing of 
previously distinct populations (Bittles 2002a). 
 
The situation is very different in most developing countries, where local and regional clan, tribal 
and ethnic groupings have largely remained intact.  Thus in India, Pakistan and Bangladesh, 
which collectively account for more than 20% of the world’s population, marriage continues to 
be arranged within caste and biraderi boundaries that probably date back some 3,000 years.  In 
India alone, there are an estimated 50,000 to 60,000 separate endogamous communities (Gadgil 
et al. 1998).  Furthermore, some 25% of the population of 1,050 million are members of the 
1,600+ scheduled tribes and castes that exist outside the Hindu caste system (Bhasin et al. 
1992), and a further 130 million persons are Muslim.  In effect, each of these groupings, 
whether Hindu caste or non-caste, Muslim, Christian, Buddhist, Sikh, Jain or Parsi, form 
separate breeding pools.  The net result is that while disease mutations of ancient origin may be 
distributed throughout the population, those which have arisen more recently may be restricted 
or even unique to individual ethnic groups, sub-castes, tribes or clans (Bittles 2002b). 
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Gene mutations can be rapidly transmitted and increase to high frequency via genetic drift 
within social, religious and geographical isolates of this type, especially in communities that are 
numerically small.  Due to the restricted nature of their gene pools, there also is a high 
probability that by chance alone, couples who marry are biological relatives, an extreme 
example being the remote island of Tristan da Cunha in the South Atlantic, which was colonized 
in the early 19
th century (Roberts 1992).  In many developing countries, there also is a strong 
preference for consanguineous marriage, and so in North and Sub-Saharan Africa, the Middle 
East, West, Central and South Asia, 20% to over 50% of marital unions are intra-familial, most 
commonly contracted between first cousins (http://www.consang.net ; Bittles 2001).  
 
Community Genetics and Public Health Genetics 
 
The influence of these various factors and the increasing contribution of genome-based 
information to health studies have led to the development of new, multidisciplinary approaches 
to the role of genetics in medicine. Community Genetics starts from a medical 
genetics/community medicine perspective and seeks to provide guidelines for the establishment 
and surveillance of programmes to prevent and control the adverse effects of human genetic 
disorders (Henneman et al. 2001).  These programmes can variously be run at local, national 
and regional levels, and they emphasize strengthening the role of primary health care, 
integrating interventions into reproductive health programmes, and ensuring the feasibility and 
cost-effectiveness of preventive strategies (Alwan and Modell 1997).  As its name suggests, 
Public Health Genetics derives from a broader public health background and aims to prevent 
mortality, morbidity and disability of genetic origin by integrating genome-based information 
into existing public health practice (Khoury et al. 2000; Beskow et al. 2001).  The perceived 
remit of Public Health Genetics thus encompasses single locus disease genes, polygenic, 
multifactorial disorders, and pharmacogenomics, i.e. the interaction of genes with therapeutic 
agents. 
 
Community Genetics has tended to concentrate on providing services to populations where 
genetic disorders are present at high frequency and on establishing community-specific care 
programmes.  This includes communities in developing countries.  By comparison, Public 
Health Genetics has been more concerned with providing solutions to the growing genetic 
problems faced by the populations of industrialized countries and calls on the services of a 
wider range of non-clinical, health-related professionals, including groups such as 
anthropologists, lawyers and social workers.  Both disciplines are dependent on population- and 
subpopulation-based studies, and they also share a strong emphasis on the need for informed 
public consultation and the development of rigorous ethical guidelines. 
 
The sharp community-based subdivisions characteristic of most developing countries can 
effectively delineate the distribution and frequency of specific disorders, ranging from inherited 
anaemias (de Silva et al. 2000), to cancers (Shanmugaratnam et al. 1989), and pre-disposition to 
major infectious diseases (Pitchappan 2002).  Although data on regional origins are collected 
from patients in many of these countries, very limited attention has been paid to genetic 
differences between ethnic groups or specific communities.  Where disorders are community-
specific, this type of information is essential if efficient preventive programmes are to be 
introduced.  However, any such information-gathering exercise has to be conducted with due 
caution and discretion, lest families or even entire communities become inadvertently 
stigmatized on the grounds that they carry a gene(s) for a particular genetic disorder (Bittles 
2003b). 
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Similar problems stemming from inadequate definitions of ethnic subpopulations have been a 
major problem in the industrialized countries, with a common tendency to broadly refer to 
individuals as being of ‘Maghrebian’ or ‘South Asian’ origin.  By ignoring the very marked 
genetic subdivisions that exist within these supra-regional categories, disease prevalence 
surveys may be of little practical relevance.  There also has been over-emphasis on the adverse 
effects of consanguineous marriage, perhaps fuelled by historical suspicions of inbreeding in 
western countries (Bittles 2003a).  This prejudice is commonly accompanied by a failure to 
recognize the potential effects of community endogamy and the outcomes of random inbreeding 
on the prevalence of genetic disorders. 
 
Discussion 
 
The changing profile of human disease has been especially apparent in the countries of the Gulf 
region, where traditional tribal and clan endogamy and high levels of consanguineous marriage 
have resulted in the accumulation of specific disease mutations within individual communities 
(Teebi and Farag 1997).  In previous generations, the adverse outcomes of these mutations 
would largely have been obscured by the high rates of infant mortality typical of developing 
countries.  But since development of the oil and petrochemical industries within the region 
during the mid- to late 20
th century and the introduction of high technology health care 
programmes, a wide range of genetic disorders has increasingly been diagnosed. 
 
The financial and health infrastructure problems associated with genetic diseases have yet to 
fully emerge in developing countries.  However, two examples illustrate their potential scale.  In 
Pakistan 5,000+ infants with β–thalassaemia, an usually severe inherited form of anaemia, are 
born each year and require regular blood transfusions to survive.  The yearly blood requirement 
of each annual birth cohort of affected children is 90,000 units of blood, with an associated cost 
per patient for chelation therapy to remove excess iron of US$4,400 (Ahmed et al. 2002).  This 
compares with the annual GNP per person in Pakistan of US$1,860 (PRB 2002).  In related 
terms, in Indonesia it has been estimated that the blood transfusion requirement for patients with 
severe forms of β–thalassaemia is now approaching 1.25 to 1.5 million units per year (WHO 
2002).  Demands of this nature will be extremely difficult to sustain, especially in developing 
countries where blood may be infected with a range of viruses and blood banking and testing 
facilities are limited, hence the central emphasis on disease prevention in Community Genetics 
programmes. 
 
In fact, a similar if less acute scenario also applies in many industrialized countries, where β–
thalassaemia mutations have been maintained in the gene pool of countries such as Italy and 
Greece as a historical protective response to the selective pressure of the malaria parasite 
Plasmodium falciparum.  In Northern Europe, North America and Australasia, α- and β–
thalassaemia mutations also may be present at high frequency within migrant communities from 
regions of the world where malaria was or remains endemic, once again placing major demands 
on supplies of blood for remedial transfusion. 
 
Besides social and economic considerations, the growing changes in human disease profiles 
have exposed poor levels of understanding of genetic disorders among many clinicians in major 
industrialized countries (Baird 2001).  This problem is even greater in developing countries, in 
part because genetic disease is still mistakenly considered to be of limited significance and 
accordingly, training in genetics is given low priority.  As a result, the need for the formal 
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training of clinicians and non-clinical support staff and for effective public education 
programmes is all the more pressing in many less affluent countries (Verma and Bijarnia 2002). 
 
Although genetics can be expected to contribute positively to future programmes for the 
maintenance of human health, and particularly to the prevention of currently intractable age-
related disorders, these goals will not be achieved as a matter of course.  There are major 
concerns that the principal targets for genomic research will be chosen primarily on commercial 
grounds rather than on the basis of need, and the patenting of disease mutations has served to 
heighten these suspicions.  As a current example, the tactics employed in the marketing of 
BRCA1 mutation testing for breast cancer, the lack of ensured provision for pre-and post-test 
counselling, and the scale of charges involved all have been subject to strong criticism, but as 
yet to limited avail.  Although these matters have so far principally affected the industrialized 
world, in developing countries there are worries that medical staff may be encouraged to adopt 
expensive therapeutic treatments when prevention would provide a more appropriate and low-
cost, if less glamorous, alternative (Alwan and Modell 2003). 
 
A recent World Health Organization publication proposed that the health rewards expected to 
flow from the commercial development of genomics should be equitably distributed between 
the industrialized and developing countries (WHO 2002).  Recent experience would tend to 
suggest that while such altruistic behaviour would be welcomed by many, the proposal might 
not receive unreserved support from the companies concerned and their shareholders.  In part, 
difficulties have arisen because of legal discrepancies between the countries and political and 
trade groupings most immediately concerned.  It is also a fact of life that a highly focused and 
financially robust private company, with good international connections and offering substantial 
financial returns to potential backers, can act with a determination and dispatch that 
governmental agencies simply cannot match. 
 
If genome- and proteome-based research is to proceed for the greater good of all, decisions as to 
the targets and directions of research, its timing, sources and extent of funding, and how 
outcome benefits can be efficiently and equitably distributed, require informed and non-partisan 
counsel.  Manifestly, this is neither the realm nor the primary concern of commercial 
enterprises, and in recent years the governments of most industrialized countries have 
demonstrated a greatly diminished interest in tackling issues of this nature.  It is, however, 
precisely the type of critical area where IUBS, ICSU and other representative international 
scientific and medical bodies are uniquely placed to act, given their ready access to the requisite 
cross-disciplinary, trans-national expertise.  Far-sighted and principled decision-making on the 
future course of genomic research across the Biological Sciences is sorely needed.  This is 
surely a task that merits the urgent attention of IUBS. 
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